Table 3

Treatment Settings
Number of chemotherapy lines in recurrent or metastatic setting Among the whole cohort (N = 198) Among patients eligible for inclusion in a clinical trial (N = 131)
No. of patients (%) No. of patients (%)
1 74 (37) 33 (25)
2 47 (24) 37 (28)
3 44 (22) 33 (25)
4 23 (12) 19 (15)
5 or more 10 (5) 9 (7)
Chemotherapy drug used
Taxanes 177 (89) 122 (93)
Including recurrent or metastatic setting 162 (82) 116 (89)
CDDP or Carboplatin 185 (93) 127 (97)
Including recurrent or metastatic setting 154 (78) 114 (87)
5FU 78 (39) 62 (47)
Including recurrent or metastatic setting 36 (18) 32 (24)
Cetuximab 144 (73) 103 (79)
Including recurrent or metastatic setting 134 (68) 100 (76)
Capecitabine in recurrent or metastatic setting 27 (14) 23 (18)
Methotrexate in recurrent or metastatic setting 67 (34) 39 (30)
Novel agent tested in a clinical trial in recurrent or metastatic setting 27 (14) 27 (21)
Drug combination used in first line of the recurrent/metastatic disease
Platinum based combination 143 (72) 103 (79)
Cisplatin + taxanes 46 (23) 40 (31)
Carboplatin + taxanes 69 (35) 40 (31)
Platinum without taxanes 28 (14) 23 (18)
Including CDDP 5FU and cetuximab combination 11 (6) 10 (8)
Taxanes and cetuximab combination 14 (7) 8 (6)
Monotherapy 34 (17) 13 (10)
Clinical trials testing not approved regimens 7 (4) 7 (5)

CDDP = Cisplatin ; 5FU = 5-Fluorouracil.

Péron et al.

Péron et al. BMC Cancer 2014 14:504   doi:10.1186/1471-2407-14-504

Open Data